Flagship Pioneering, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Flagship Pioneering, LLC reported 7 stock positions worth $1.5 billion. Its top holding was Moderna (MRNA) at 67.6% of the portfolio, followed by Sana Biotechnology (SANA, 16.4%) and Omega Therapeutics (OMGAQ, 7.0%). Compared with Q4 2023, it added to 1 and reduced 1. The biggest buy was Syros Pharmaceuticals (SYRS, shares −0%) and the biggest sale Denali Therapeutics (DNLI, shares −41%).
- Most Recent 13F
- Q2 2026
- Location
- CAMBRIDGE, MA
- CIK
- 0001400240
- Portfolio Value
- $1.5B (Q1 2024)
- SEC Filing
- 0000950123-24-005589 ↗ filed May 15, 2024
Holdings Value
Holdings 7 stocks · $1.5B
| MRNA Moderna Inc. | 67.56% | 9,666,038 | $1.0B | No change |
| SANA Sana Biotechnology Inc. | 16.40% | 25,001,856 | $250.0M | No change |
| OMGAQ Omega Therapeutics Inc. | 7.00% | 29,225,579 | $106.7M | No change |
| FHTX Foghorn Therapeutics Inc. | 5.58% | 12,674,120 | $85.0M | No change |
| DNLI Denali Therapeutics Inc. | 1.84% | 1,364,516 | $28.0M | Reduce -41.2% |
| MCRB Seres Therapeutics Inc. | 1.17% | 23,117,045 | $17.9M | No change |
| SYRS Syros Pharmaceuticals Inc. | 0.45% | 1,293,849 | $6.9M | Add +0.0% |
Portfolio Sells Q4 2023 → Q1 2024
| DNLI Denali Therapeutics Inc. | Reduce -41.2% | 1.84% | −1.92 |
Portfolio Buys Q4 2023 → Q1 2024
| SYRS Syros Pharmaceuticals Inc. | Add +0.0% | 0.45% | −0.31 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 5 | $1.5B | GENB, MRNA, SANA, FHTX, MCRB |
| Q1 2026 | 5 | $1.2B | GENB, MRNA, SANA, FHTX, MCRB |
| Q4 2025 | 4 | $324.0M | MRNA, SANA, FHTX, MCRB |
| Q3 2025 | 4 | $292.6M | MRNA, SANA, FHTX, MCRB |
| Q2 2025 | 4 | $268.5M | MRNA, SANA, FHTX, MCRB |
| Q1 2025 | 4 | $235.8M | MRNA, FHTX, SANA, MCRB |
| Q4 2024 | 5 | $334.2M | MRNA, FHTX, SANA, OMGAQ, MCRB |
| Q3 2024 | 6 | $591.9M | MRNA, FHTX, SANA, OMGAQ, MCRB |
| Q2 2024 | 6 | $843.4M | MRNA, SANA, FHTX, OMGAQ, MCRB |
| Q1 2024 | 7 | $1.5B | MRNA, SANA, OMGAQ, FHTX, DNLI |